product name Neostigmine Bromide
Description: Neostigmine Bromide is a reversible acetylcholinesterase inhibitor. It is marketed under the brand name Prostigmin among others, is a medication used to treat myasthenia gravis, Ogilvie syndrome, and urinary retention without the presence of a blockage. It is also used together with atropine to end the effects of neuromuscular blocking medication of the non-depolarizing type.
References: Clin Colon Rectal Surg. 2005 May;18(2):96-101
303.2
Formula
C12H19N2O2.Br
CAS No.
114-80-7
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: <1 mg/mL
Water: 60 mg/mL (197.9 mM)
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID::http://www.ncbi.nlm.nih.gov/pubmed/19390942
In Vitro |
In vitro activity: Kinase Assay: Cell Assay: |
---|---|
In Vivo | |
Animal model | |
Formulation & Dosage | |
References |
Author: Sodium channel
product name Neostigmine Bromide
Description: Neostigmine Bromide is a reversible acetylcholinesterase inhibitor. It is marketed under the brand name Prostigmin among others, is a medication used to treat myasthenia gravis, Ogilvie syndrome, and urinary retention without the presence of a blockage. It is also used together with atropine to end the effects of neuromuscular blocking medication of the non-depolarizing type.
References: Clin Colon Rectal Surg. 2005 May;18(2):96-101
303.2
Formula
C12H19N2O2.Br
CAS No.
114-80-7
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: <1 mg/mL
Water: 60 mg/mL (197.9 mM)
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID::http://www.ncbi.nlm.nih.gov/pubmed/19390942
In Vitro |
In vitro activity: Kinase Assay: Cell Assay: |
---|---|
In Vivo | |
Animal model | |
Formulation & Dosage | |
References |